General Dynamics has been building submarines and tanks since 1899. Rocket Lab has been building rockets since 2006 and still hasn't launched its next-generation Neutron vehicle. Both companies sit in the same Aerospace & Defense industry, and both claim to be the fundamentally stronger bet right now. Only one of them actually has the balance sheet to back that up, and it's not the one with the better stock chart.
Three rounds decide this: Health Score, Performance Score, and Risk Score, one round each.
Here's both companies side by side before the numbers start.
Both stocks get compared across the three scores that decide who's actually built to last: fundamental health, delivered performance, and how much risk each one is carrying to get there.
Round 1: Health Score, who's actually built to last
General Dynamics (GD) carries a 7.4 Health Score. Rocket Lab (RKLB) sits at 1.7, one of the widest Health Score gaps between two stocks in the same industry.
The gap is backed by real numbers, not just a score. General Dynamics posted an 8.07% net profit margin last year, meaning it kept about $8 of actual profit for every $100 in sales, and a 16.43% return on equity, meaning shareholders earned back roughly $16 a year for every $100 they had invested in the company. Its defense segments carried a $130.8 billion backlog on a 1.4-to-1 book-to-bill ratio as of July, meaning it booked $1.40 in new orders for every $1 of revenue delivered that quarter, a sign demand is still building, not fading. Rocket Lab posted a net profit margin of negative 26.87%, meaning it lost about $27 for every $100 in sales, and burned $165.5 million in operating cash flow over the same stretch, spending more cash running the business than it brought in. Its revenue is growing fast, up 62% year over year last quarter, but growth and profitability are two different questions, and Health Score is asking the second one.
Round 2: Performance Score, who's actually delivered
Flip the scoreboard and Rocket Lab wins convincingly. Its Performance Score sits at 8.1 against General Dynamics' 5.9. The stock is up 1,164% over three years and 301% over five, against General Dynamics' 60% and 85% over the same windows.
That gap traces straight back to what each stock has actually been pricing in. General Dynamics has compounded steadily on a business that already prints profit today. Rocket Lab's return has come almost entirely from the market re-rating a story that hasn't been delivered yet, Neutron's own timeline has already slipped from mid-2026 to a Q4 pad delivery, with the actual first launch now looking more likely in 2027, and the stock has swung hard on every update about it.
Round 3: Risk Score, what the performance actually cost
One round each, and Risk Score breaks the tie. General Dynamics carries a Risk Score of 2.1, near the low end of the entire scale. Rocket Lab sits at 10, the maximum. Risk Score is built from three things: how much a stock actually swings day to day, how deep its worst recent decline went, and how it moves relative to the broader market.
General Dynamics trades with a beta of 0.32, meaning its stock has historically moved only about a third as much as the overall market on a given swing, and a standard deviation of 5.08%, meaning its price has typically bounced around by about that much. Its worst peak-to-trough decline over the past year was 4.78%, a stretch most long-term holders would barely notice. Rocket Lab trades with a beta of 2.61, meaning it swings roughly two-and-a-half times harder than the market in either direction, and a standard deviation of 39.28%, nearly eight times wider than General Dynamics'. Its worst decline over the past year hit 14.66%, more than three times deeper. Every one of those numbers points the same direction: Rocket Lab's entire investment case rides on Neutron actually reaching orbit, and until it does, the stock swings accordingly.
Final score: General Dynamics 2, Rocket Lab 1
General Dynamics takes the overall win because two of the three scores that matter, fundamental health and risk, point the same direction, and the one score it loses, performance, comes from a business built to be volatile in the first place. Rocket Lab's case isn't weak, a 62% year-over-year revenue jump and a swelling launch backlog are real, but the entire investment thesis is still waiting on one rocket that keeps missing its own timeline.
Numbers on a page are one thing. Watching a 0.32 beta stock and a 2.61 beta stock trade side by side is another.
So where does that leave you? General Dynamics is the pick if what you want is a defense-industry compounder with a backlog measured in decades and a risk profile near the bottom of the scale. Rocket Lab is the pick if you believe Neutron actually reaches the launch pad and starts converting a swelling backlog into revenue, and you're comfortable carrying maximum-rated risk while you wait. Neither read is a signal to buy either stock, it's a scorecard built on where each company stands today, not a guarantee of where either one trades once Neutron either flies or slips again.
